BridgeBio Pharma, Inc. is a biotechnology company that focuses on developing medicines for genetic diseases. The company's pipeline includes over 20 development programs, including treatments for diseases such as achondroplasia, adrenoleukodystrophy, and cystinosis. BridgeBio Pharma, Inc. also has a subsidiary, Eidos Therapeutics, which focuses on developing treatments for transthyretin amyloidosis. The company was founded in 2015 and is headquartered in Palo Alto, California.